NEWS

ALS expert Prof. Peter Andersen joins Avrion Advisory Board

Prof. Peter Andersen MD, renowned ALS expert in particular of disease associated with misfolded SOD1, joins the Scientific Advisory Board of Avrion. Read More…

Avrion at Swiss Biotech Day 2021

Avrion will present at the prestigious Swiss Biotech Day on September 7 2021 Read More…

Avrion selected for Venture Leaders Biotech

Avrion selected as one of ten Startups to showcase Swiss biotech innovation on the global stage as part of Venture Leaders Biotech 2021 and the Swiss National Startup team. Read More…

Avrion welcomes Prof. Isabelle Décosterd to Advisory Board

Prof. Décosterd the director of the Pain Center at the University Hospital of Lausanne (CHUV). Read More…

Avrion - 1 of 5 neurology companies you need to know about

CM Life Sciences highlights Avrion Therapeutics as one of five exciting neurology companies Read More…

Avrion at EPFL Startup Champions

Attend for free online and hear more about Avrion from CEO Maximilien Murone during EPFLs Startup Champions Night. Read More…

Avrion selected as one of the top 6 Swiss start-ups in which to invest by Bilan

Bilan magazine, the influential Swiss and international business and economy publication, has selected Avrion Therapeutics as one the six best start-ups in which to invest in 2021 from a comparison of 270 new Swiss companies. Read More…

Avrion Therapeutics - Join us in the fight against ALS

New Study - ALS Gene Therapy in Astrocytes enables re-innervation and improves muscles

Avrion CSO Dr. Bernard Schneider authors a new study demonstrating the potent effects of specifically targeting disease causing SOD1 by gene therapy in the astrocytes of a mouse model of the motor neuron disease ALS. The study shows that specifically targeting SOD1 in this cell type enables plasticity and re-innervation, increasing the number and activity of neuromuscular junctions, the essential connections between motor neurons and muscles, thereby allowing the preservation of muscle function. The data from this study have been incorporated in the design of AVR-001, Avrion's first gene therapy product aimed to treat ALS. Read More…

Avrion Therapeutics elects Gael Hedou as new Chairperson of Board

Avrion Therapeutics AG elects Dr. Gael Hedou, founder and former CEO of Relief Therapeutics Holding AG, as new Chairman of the Board of Directors. Read More…
AVRION UPDATES